First Line Ovarian Cancer Treatment - Cohort Study

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Collaborator: Roche Pharma AG
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients aged 18 years and over,

• Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy

• Patients should be informed of the study orally and should not have any objection their data to be processed.

Exclusion Criteria:

• Patient participation in a clinical trial

• Patient non-affiliated to a social security scheme.